ECSP15051434A - Composición farmacéutica de dosis baja - Google Patents

Composición farmacéutica de dosis baja

Info

Publication number
ECSP15051434A
ECSP15051434A ECIEPI201551434A ECPI201551434A ECSP15051434A EC SP15051434 A ECSP15051434 A EC SP15051434A EC IEPI201551434 A ECIEPI201551434 A EC IEPI201551434A EC PI201551434 A ECPI201551434 A EC PI201551434A EC SP15051434 A ECSP15051434 A EC SP15051434A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
deferasirox
low dose
dose pharmaceutical
composition comprises
Prior art date
Application number
ECIEPI201551434A
Other languages
English (en)
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ECSP15051434A publication Critical patent/ECSP15051434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención proporciona una composición farmacéutica de dosis baja que comprende deferasirox o un derivado farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables. Una dosis unitaria de la composición farmacéutica comprende desde aproximadamente 50 mg hasta aproximadamente 100 mg de deferasirox, desde aproximadamente 150 mg hasta aproximadamente 200 mg de deferasirox o desde aproximadamente 260 mg hasta aproximadamente 350 mg de deferasirox. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox, puede usarse para tratar sobrecarga de hierro crónica o para tratar toxicidad por plomo. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox y deferiprona, puede usarse para tratar toxicidad por plomo. Esta invención también proporciona un procedimiento para preparar la composición farmacéutica de dosis baja, comprendiendo el procedimiento: disolver o adsorber o combinar deferasirox y al menos un excipiente para producir una dispersión de deferasirox; y procesar la dispersión para producir una forma de dosificación deseada.
ECIEPI201551434A 2013-05-10 2015-12-10 Composición farmacéutica de dosis baja ECSP15051434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1696MU2013 IN2013MU01696A (es) 2013-05-10 2014-05-08

Publications (1)

Publication Number Publication Date
ECSP15051434A true ECSP15051434A (es) 2017-05-31

Family

ID=50979804

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201551434A ECSP15051434A (es) 2013-05-10 2015-12-10 Composición farmacéutica de dosis baja

Country Status (18)

Country Link
US (4) US20160120847A1 (es)
EP (1) EP2994131A1 (es)
JP (1) JP2016518398A (es)
CN (1) CN105377256A (es)
AP (1) AP2015008875A0 (es)
AU (1) AU2014264421A1 (es)
BR (1) BR112015028257A2 (es)
CA (1) CA2911671A1 (es)
EC (1) ECSP15051434A (es)
HK (1) HK1215191A1 (es)
IN (1) IN2013MU01696A (es)
MX (1) MX2015015553A (es)
PE (1) PE20151934A1 (es)
PH (1) PH12015502557A1 (es)
RU (1) RU2015149544A (es)
SG (1) SG11201509308TA (es)
WO (1) WO2014181108A1 (es)
ZA (1) ZA201403276B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2989145A1 (en) * 2015-06-17 2016-12-22 Dispersol Technologies, Llc Improved formulations of deferasirox and methods of making the same
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
EP3429562A1 (en) * 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
CN105853367B (zh) * 2016-05-10 2019-07-12 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
EP3481390A4 (en) * 2016-07-05 2020-03-04 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
AU2018283250B2 (en) 2017-06-16 2022-09-01 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
CA3172668A1 (en) * 2017-10-25 2019-05-02 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
CN109646423A (zh) * 2018-12-03 2019-04-19 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090142395A1 (en) * 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
CA2846436A1 (en) * 2011-09-23 2013-03-28 Universitat Stuttgart Serum half-life extension using immunoglobulin binding domains

Also Published As

Publication number Publication date
BR112015028257A2 (pt) 2017-07-25
AU2014264421A1 (en) 2015-12-03
IN2013MU01696A (es) 2015-06-26
JP2016518398A (ja) 2016-06-23
US20160158202A1 (en) 2016-06-09
EP2994131A1 (en) 2016-03-16
RU2015149544A (ru) 2017-06-16
CA2911671A1 (en) 2014-11-13
CN105377256A (zh) 2016-03-02
AP2015008875A0 (en) 2015-11-30
ZA201403276B (en) 2015-07-29
US20160120847A1 (en) 2016-05-05
PE20151934A1 (es) 2015-12-26
MX2015015553A (es) 2016-06-17
SG11201509308TA (en) 2015-12-30
HK1215191A1 (zh) 2016-08-19
US20170095453A1 (en) 2017-04-06
US20170312254A1 (en) 2017-11-02
PH12015502557A1 (en) 2016-02-22
WO2014181108A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
ECSP15051434A (es) Composición farmacéutica de dosis baja
DOP2019000201A (es) Compuestos inhibidores del vih
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
MX2015010829A (es) Compuestos terapeuticos y sus usos.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
AR108792A1 (es) Composiciones que comprenden timolol
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.